{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:41:19Z","timestamp":1782819679022,"version":"3.54.5"},"reference-count":31,"publisher":"Medknow","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["smedj"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.11622\/smedj.2019028","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T09:04:03Z","timestamp":1552295043000},"page":"364-378","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review"],"prefix":"10.4103","volume":"60","author":[{"given":"T","family":"Chandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Venkatachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2581","published-online":{"date-parts":[[2019,7]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s001980170121","article-title":"Hip fracture incidence rates in Singapore 1991-1998","volume":"12","author":"LK","year":"2001","unstructured":"1. Koh LK, Saw SM, Lee JJ, Leong KH, Lee J; National Working Committee on Osteoporosis. Hip fracture incidence rates in Singapore 1991-1998. Osteoporos Int 2001; 12:311-8.","journal-title":"Osteoporos Int"},{"key":"ref1","unstructured":"2. International Osteoporosis Foundation. The Asian audit: epidemiology, costs and burden of osteoporosis in Asia 2009. Available at: https:\/\/www.iofbonehealth.org\/sites\/default\/files\/PDFs\/Audit%20Asia\/Asian_regional_audit_2009.pdf. Accessed May 3, 2016."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00198-009-1008-9","article-title":"Cortical and trabecular architecture are altered in postmenopausal women with fractures","volume":"20","author":"Sornay-Rendu","year":"2009","unstructured":"3. Sornay-Rendu E, Boutroy S, Munoz F, Bouxsein ML. Cortical and trabecular architecture are altered in postmenopausal women with fractures. Osteoporos Int 2009; 20:1291-7.","journal-title":"Osteoporos Int"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Dhainaut A, Hoff M, Syversen U, Haugeberg G. Cortical hand bone porosity and its association with distal radius fracture in middle aged and elderly women. PLoS One 2013; 8:e68405.","DOI":"10.1371\/journal.pone.0068405"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0140-6736(10)60320-0","article-title":"Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study","volume":"375","author":"Zebaze","year":"2010","unstructured":"5. Zebaze RM, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 2010; 375:1729-36.","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","unstructured":"6. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337-42.","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","unstructured":"7. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93:2149-57.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","unstructured":"8. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-76.","journal-title":"Cell"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40618-014-0124-3","article-title":"Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods","volume":"37","author":"Messori","year":"2014","unstructured":"9. Messori A, Fadda V, Maratea D, Trippoli S, Marinai C. Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods. J Endocrinol Invest 2014; 37:769-73.","journal-title":"J Endocrinol Invest"},{"key":"ref9","unstructured":"10. Migliore A, Broccoli S, Massafra U, Cassol M, Frediani B. Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis. Eur Rev Med Pharmacol Sci 2013; 17:658-67."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1210\/jc.2013-3795","article-title":"Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis","volume":"99","author":"Mandema","year":"2014","unstructured":"11. Mandema JW, Zheng J, Libanati C, Perez Ruixo JJ. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis. J Clin Endocrinol Metab 2014; 99:3746-55.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1210\/jc.2011-3060","article-title":"Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis","volume":"97","author":"Murad","year":"2012","unstructured":"12. Murad MH, Drake MT, Mullan RJ, et al. Clinical review. Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2012; 97:1871-80.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s00198-014-2692-7","article-title":"Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate","volume":"25","author":"Brown","year":"2014","unstructured":"13. Brown JP, Roux C, Ho PR, et al. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporos Int 2014; 25:1953-61.","journal-title":"Osteoporos Int"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1742-1241.2011.02806.x","article-title":"Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis","volume":"66","author":"Lin","year":"2012","unstructured":"14. Lin T, Wang C, Cai XZ, et al. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract 2012; 66:399-408.","journal-title":"Int J Clin Pract"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","unstructured":"15. Roux C, Hofbauer LC, Ho PR, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 2014; 58:48-54.","journal-title":"Bone"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jocd.2008.04.001","article-title":"Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate","volume":"11","author":"Beck","year":"2008","unstructured":"16. Beck TJ, Lewiecki EM, Miller PD, et al. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom 2008; 11:351-9.","journal-title":"J Clin Densitom"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"MR","year":"2006","unstructured":"17. McClung MR, Lewiecki EM, Cohen SB, et al; AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:821-31.","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"EM","year":"2007","unstructured":"18. Lewiecki EM, Miller PD, McClung MR, et al; AMG 162 Bone Loss Study Group. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007; 22:1832-41.","journal-title":"J Bone Miner Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"PD","year":"2008","unstructured":"19. Miller PD, Bolognese MA, Lewiecki EM, et al; Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 43:222-9.","journal-title":"Bone"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","unstructured":"20. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 24:153-61.","journal-title":"J Bone Miner Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","unstructured":"21. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25:72-81.","journal-title":"J Bone Miner Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","unstructured":"22. Recknor C, Czerwinski E, Bone HG, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 2013; 121:1291-9.","journal-title":"Obstet Gynecol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/jbmr.81","article-title":"Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate","volume":"25","author":"Seeman","year":"2010","unstructured":"23. Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010; 25:1886-94.","journal-title":"J Bone Miner Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","article-title":"Differing effects of denosumab and alendronate on cortical and trabecular bone","volume":"59","author":"Zebaze","year":"2014","unstructured":"24. Zebaze RM, Libanati C, Austin M, et al. Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone 2014; 59:173-9.","journal-title":"Bone"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s00198-015-3174-2","article-title":"Denosumab versus zoledronic acid in patients previously treated with zoledronic acid","volume":"26","author":"Anastasilakis","year":"2015","unstructured":"25. Anastasilakis AD, Polyzos SA, Gkiomisi A, et al. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporos Int 2015; 26:2521-7.","journal-title":"Osteoporos Int"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, Jonsson B. Intervention thrsholds for osteoporosis in the UK. Bone 2005: 36:22-32.","DOI":"10.1016\/j.bone.2004.08.018"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/GME.0b013e31828f5e5d","article-title":"Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study","volume":"21","author":"Kendler","year":"2014","unstructured":"27. Kendler DL, Macarios D, Lillestol MJ, et al. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. Menopause 2014; 21:25-32.","journal-title":"Menopause"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Palacios S, Agodoa I, Bonnick S, et al. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate. J Clin Endocrinol Metab 2015; 100:E487-92.","DOI":"10.1210\/jc.2014-3594"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","unstructured":"29. Nakamura T, Matsumoto T, Sugitomo T, et al. Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 2014; 99:2599-607.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","unstructured":"30. Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012; 27:694-701.","journal-title":"J Bone Miner Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.afos.2016.03.003","article-title":"Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis","volume":"2","author":"Benjamin","year":"2016","unstructured":"31. Benjamin B, Benjamin MA, Swe M, Sugathan S. Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis. Osteoporos Sarcopenia 2016; 2:77-81.","journal-title":"Osteoporos Sarcopenia"}],"container-title":["Singapore Medical Journal"],"original-title":[],"link":[{"URL":"http:\/\/www.smj.org.sg\/article\/efficacy-and-safety-denosumab-compared-bisphosphonates-improving-bone-strength","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T10:49:43Z","timestamp":1660042183000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.smj.org.sg\/article\/efficacy-and-safety-denosumab-compared-bisphosphonates-improving-bone-strength"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7]]},"published-print":{"date-parts":[[2019,7]]}},"URL":"https:\/\/doi.org\/10.11622\/smedj.2019028","relation":{},"ISSN":["0037-5675"],"issn-type":[{"value":"0037-5675","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}